{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:11:03Z","timestamp":1790194263285,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejim.2026.106773","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:04:17Z","timestamp":1771650257000},"page":"106773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["How to monitor disease progression in ATTR amyloid cardiomyopathy: Implications for clinical practice and trial design"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-0825","authenticated-orcid":false,"given":"Aldostefano","family":"Porcari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah AM","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ejim.2026.106773_bib0001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2026.106773_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"10.1016\/j.ejim.2026.106773_bib0003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejim.2026.106773_bib0004","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","article-title":"Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration","volume":"10","author":"Porcari","year":"2025","journal-title":"JAMa Cardiol"},{"key":"10.1016\/j.ejim.2026.106773_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"36","key":"10.1016\/j.ejim.2026.106773_bib0006","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejim.2026.106773_bib0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.106773_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2026.106773_bib0009","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.106773_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.hfc.2024.03.005","article-title":"Specific therapy in transthyretin amyloid cardiomyopathy","volume":"20","author":"Saro","year":"2024","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ejim.2026.106773_bib0012","series-title":"Treatment of ATTR amyloidosis: from stabilizers to gene editing BT - Cardiac Amyloidosis: diagnosis and treatment","first-page":"78","author":"Porcari","year":"2024"},{"issue":"6","key":"10.1016\/j.ejim.2026.106773_bib0013","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.106773_bib0014","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106773_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.70071","article-title":"Clinical phenotype and prognosis of real-world patients with wild-type ATTR amyloidosis with heart involvement treated with Tafamidis","author":"Porcari","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.ejim.2026.106773_bib0016","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106773_bib0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])","volume":"148","author":"Miller","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2026.106773_bib0018","series-title":"Presented at: international symposium on amyloidosis. May 26\u201330, 2024, Rochester, MN, USA, Poster PC122. Accessed March 4","article-title":"Higher risk of mortality in previously hospitalized patients: insights from ATTRibute-CM","author":"Masri","year":"2025"},{"key":"10.1016\/j.ejim.2026.106773_bib0019","article-title":"Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy","author":"Zeldin","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10.1016\/j.ejim.2026.106773_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ejim.2026.106773_bib0021","first-page":"61","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ejim.2026.106773_bib0022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jacc.2016.09.936","article-title":"Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials","volume":"68","author":"Ferreira","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.106773_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719870084","article-title":"6-minute walking test: a useful tool in the management of heart failure patients","volume":"13","author":"Giannitsi","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.ejim.2026.106773_bib0024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/euhj.2000.2310","article-title":"Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?","volume":"22","author":"Opasich","year":"2001","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106773_bib0026","doi-asserted-by":"crossref","first-page":"JC30","DOI":"10.7326\/J24-0004","article-title":"In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo","volume":"177","author":"Masri","year":"2024","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.ejim.2026.106773_bib0027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ehf2.13749","article-title":"N-terminal pro-B-type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction","volume":"9","author":"Januzzi","year":"2022","journal-title":"ESC Hear Fail"},{"issue":"30","key":"10.1016\/j.ejim.2026.106773_bib0029","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ejim.2026.106773_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.ejim.2026.106773_bib0031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","article-title":"Cardiac troponin in patients with light chain and transthyretin Cardiac amyloidosis: JACC: CardioOncology State-of-the-art review","volume":"6","author":"De Michieli","year":"2024","journal-title":"JACC CardioOncology"},{"issue":"8","key":"10.1016\/j.ejim.2026.106773_bib0033","article-title":"High-sensitivity cardiac troponin I for risk stratification in wild-type transthyretin amyloid cardiomyopathy","volume":"18","author":"De Michieli","year":"2025","journal-title":"Circ Hear Fail"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0034","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMa Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106773_bib0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Witteles RM. Effect of Tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncology"},{"issue":"9689","key":"10.1016\/j.ejim.2026.106773_bib0036","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2026.106773_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0038","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10.1016\/j.ejim.2026.106773_bib0039","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2026.106773_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of Canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106773_bib0041","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ejhf.3245","article-title":"The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: is the time ripe for clinical use of sodium\u2013glucose cotransporter 2 inhibitors?","volume":"26","author":"Porcari","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.ejim.2026.106773_bib0042","first-page":"9","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Hear Fail"},{"issue":"4","key":"10.1016\/j.ejim.2026.106773_bib0043","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc ImAging"},{"issue":"14","key":"10.1016\/j.ejim.2026.106773_bib0044","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ejim.2026.106773_bib0045","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.ejim.2026.106773_bib0046","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/ehjci\/jeae060","article-title":"Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis","volume":"25","author":"Tomasoni","year":"2024","journal-title":"Eur Hear j Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0047","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ehf2.13093","article-title":"Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis","volume":"8","author":"Fagot","year":"2021","journal-title":"ESC Hear Fail"},{"issue":"2","key":"10.1016\/j.ejim.2026.106773_bib0048","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2459\/JCM.0000000000001690","article-title":"Echocardiographic index of left ventricular performance for prognostication in transthyretin cardiac amyloidosis: the central role of stroke volume index","volume":"26","author":"Serenelli","year":"2025","journal-title":"J Cardiovasc Med (Hagerst)"},{"key":"10.1016\/j.ejim.2026.106773_bib0049","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.70073","article-title":"Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis","author":"Venneri","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of Tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: A post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMa Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2026.106773_bib0051","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jacc.2025.06.022","article-title":"Effects of Vutrisiran on cardiac function and outcomes in patients with transthyretin amyloidosis with cardiomyopathy","volume":"86","author":"Jering","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0052","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10741-020-09986-0","article-title":"Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle","volume":"27","author":"Porcari","year":"2020","journal-title":"Heart Fail Rev"},{"issue":"9","key":"10.1016\/j.ejim.2026.106773_bib0053","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamacardio.2023.2010","article-title":"Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping","volume":"8","author":"Ioannou","year":"2023","journal-title":"JAMa Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2026.106773_bib0054","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamacardio.2024.2555","article-title":"Redefining cardiac involvement and targets of treatment in systemic immunoglobulin AL amyloidosis","volume":"9","author":"Porcari","year":"2024","journal-title":"JAMa Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0055","first-page":"88","article-title":"Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR","volume":"14","author":"Fontana","year":"2012","journal-title":"J Cardiovasc Magn Reson J Soc Cardiovasc Magn Reson"},{"key":"10.1016\/j.ejim.2026.106773_bib0056","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf412","article-title":"Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance","author":"Patel","year":"2025","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejim.2026.106773_bib0057","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13598","article-title":"Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0058","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ejhf.1299","article-title":"Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION","volume":"21","author":"Luo","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106773_bib0059","unstructured":"Levy J.C., Teruya S., Mirabal Santos A., et al. Worsening quality of life, captured by change in KCCQ-OS, a heart failure-specific PRO, is predictive of outcomes in ATTR- CM. Presented at: American College of Cardiology Annual Scientific Session.2025, Chicago (IL,USA), Poster."},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12931-021-01895-6","article-title":"Practical guide to cardiopulmonary exercise testing in adults","volume":"23","author":"Glaab","year":"2022","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.ejim.2026.106773_bib0061","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ejhf.2016","article-title":"Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"23","author":"Nicol","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2026.106773_bib0062","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.amjcard.2019.03.035","article-title":"Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis","volume":"124","author":"Yunis","year":"2019","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106773_bib0063","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamacardio.2024.0022","article-title":"Cardiopulmonary exercise testing in evaluating transthyretin amyloidosis","volume":"9","author":"Patel","year":"2024","journal-title":"JAMa Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106773_bib0064","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11739-022-03125-3","article-title":"Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis","volume":"18","author":"Silverii","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ejim.2026.106773_bib0065","unstructured":"Porcari A., Bandera F., Sheikh A., Venneri L., Emdin E., Mansell J., et al, Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy. Presented at: European Society of Cardiology - Heart Failure 2025 Congress, Belgrade (Serbia), Oral Presentation \u201cLate-breaking science in heart failure\u201d."},{"issue":"10253","key":"10.1016\/j.ejim.2026.106773_bib0066","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejim.2026.106773_bib0067","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jchf.2025.01.020","article-title":"Cardiopulmonary exercise testing with exercise echocardiography to assess treatment response in transthyretin amyloid cardiomyopathy","volume":"13","author":"Patel","year":"2025","journal-title":"JACC Hear Fail"},{"issue":"14","key":"10.1016\/j.ejim.2026.106773_bib0068","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/heartjnl-2024-324826","article-title":"Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis","volume":"111","author":"Bampatsias","year":"2025","journal-title":"Heart"},{"issue":"15","key":"10.1016\/j.ejim.2026.106773_bib0069","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ejim.2026.106773_bib0070","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcmg.2025.03.014","article-title":"Uncertain clinical relevance of serial bone scintigraphy findings in treated transthyretin amyloid cardiomyopathy","volume":"18","author":"Razvi","year":"2025","journal-title":"JACC Cardiovasc ImAging"},{"issue":"3","key":"10.1016\/j.ejim.2026.106773_bib0071","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jaccao.2025.01.018","article-title":"Clinical phenotype and prognostic significance of frailty in transthyretin cardiac amyloidosis","volume":"7","author":"Fumagalli","year":"2025","journal-title":"JACC CardioOncology"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:12:20Z","timestamp":1780287140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"alternative-id":["S0953620526000786"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106773","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to monitor disease progression in ATTR amyloid cardiomyopathy: Implications for clinical practice and trial design","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106773"}}